CS
BHVN

Credit Suisse’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Credit Suisse’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-52,364
Closed -$7.92M – 4266
2022
Q3 		$7.92M Sell
52,364
-1,059
-2% -$157K 0.01% 1018
2022
Q2 		$7.79M Sell
53,423
-2,066
-4% -$264K 0.01% 1036
2022
Q1 		$6.58M Buy
55,489
+5,040
+10% +$629K 0.01% 1280
2021
Q4 		$6.95M Buy
50,449
+3,562
+8% +$453K ﹤0.01% 1764
2021
Q3 		$6.51M Buy
46,887
+6,534
+16% +$816K ﹤0.01% 1846
2021
Q2 		$3.95M Buy
40,353
+2,161
+6% +$175K ﹤0.01% 2284
2021
Q1 		$2.61M Sell
38,192
-36,286
-49% -$2.93M ﹤0.01% 2618
2020
Q4 		$6.38M Buy
74,478
+5,164
+7% +$438K ﹤0.01% 1902
2020
Q3 		$4.51M Sell
69,314
-11,079
-14% -$726K ﹤0.01% 1855
2020
Q2 		$5.88M Buy
80,393
+4,992
+7% +$266K ﹤0.01% 1608
2020
Q1 		$2.57M Sell
75,401
-6,527
-8% -$298K ﹤0.01% 1962
2019
Q4 		$4.46M Buy
81,928
+45,377
+124% +$2.25M ﹤0.01% 1964
2019
Q3 		$1.52M Sell
36,551
-83,291
-70% -$3.52M ﹤0.01% 2695
2019
Q2 		$5.25M Buy
119,842
+97,437
+435% +$5.49M ﹤0.01% 1727
2019
Q1 		$1.15M Buy
22,405
+1,092
+5% +$47.2K ﹤0.01% 2778
2018
Q4 		$788K Sell
21,313
-24,145
-53% -$871K ﹤0.01% 2970
2018
Q3 		$1.71M Buy
45,458
+20,239
+80% +$744K ﹤0.01% 2468
2018
Q2 		$997K Buy
25,219
+250
+1% +$7.93K ﹤0.01% 3013
2018
Q1 		$643K Buy
24,969
+14,800
+146% +$442K ﹤0.01% 3226
2017
Q4 		$274K Buy
10,169
+2,610
+35% +$71.9K ﹤0.01% 3658
2017
Q3 		$282K Buy
+7,559
New +$229K ﹤0.01% 3772

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $403M AUM 28.73% 1-Year Est. Return

Credit Suisse's BHVN Position: Q4 2022 in Review

Credit Suisse sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 52,364 shares — an estimated $7.92M sold.

Credit Suisse first reported a position in BHVN in Q3 2017 and held it in 21 quarters. The position peaked at $7.92M in Q3 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Credit Suisse reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Credit Suisse sold 52,364 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $7.92M.
  • Credit Suisse first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q3 2017 and held it in 21 quarters.
  • Credit Suisse's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $7.92M in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Credit Suisse's 13F filing for Q4 2022, filed 13 Feb 2023.